OUTCOMES OF ADULTS, ADOLESCENTS, AND CHILDREN WITH PRIMARY MEDIASTINAL B‐CELL LYMPHOMA TREATED WITH DOSE‐ADJUSTED EPOCH‐R THERAPY: a MULTICENTER RETROSPECTIVE ANALYSIS
Bibliographic record
Abstract
Introduction: Treatment with dose-adjusted EPOCH chemotherapy and rituximab (DA-EPOCH-R) has become the standard of care for primary mediastinal B-cell lymphoma (PMBCL) at many institutions despite limited data in the multi-center setting. We report a large, multi-center retrospective analysis of children and adults with PMBCL treated with DA-EPOCH-R to characterize outcomes, specifically assess both pediatric and adult patients, and to evaluate potential prognostic factors. Methods: 156 patients with PMBCL treated with DA-EPOCH-R across 24 academic medical centers were assessed, including 38 children and 118 adults. All patients received at least one cycle of DA-EPOCH-R. Radiation therapy was administered at the completion of DA-EPOCH-R in 14.7% of patients. Results: With median follow-up of 22.6 months (range 2.7-101.0 months), the estimated 3-year EFS is 85.9% (95% CI 80.3-91.5) and OS is 95.4% (95% CI 91.8-99.0). Outcomes were similar in pediatric and adult patients. Pediatric patients were more likely to present with bulky mediastinal disease and were more likely to be escalated to at least dose level 4. Thrombotic complications were reported in 28.2% of patients and were more common in pediatric patients (45.9% vs. 22.9%, p = 0.011). The sites of thromboses included: upper extremity (n = 22), internal jugular vein or superior vena cava (n = 10), intracardiac (n = 5), pulmonary embolism (n = 5), and lower extremity (n = 2). Seventy-five percent of patients had a negative FDG-PET scan at the completion of DA-EPOCH-R, defined as Deauville score 1-3. Negative FDG-PET at end-of-therapy was associated with improved EFS (95.4% vs. 54.9%, p < 0.001). Conclusions: Our multicenter data support the use of DA-EPOCH-R for the treatment of PMBCL in children, adolescents, and adults with PMBCL. The high rate of thrombosis suggests that prophylactic anticoagulation should be considered in this setting. Patients with a positive end-of-therapy FDG-PET scan have an inferior outcome and may benefit from augmented or novel therapy. Keywords: DA-R-EPOCH; primary mediastinal large B-cell lymphoma (PMLBCL).
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".